Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 70/100

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Wednesday, April 30, 2025 2 min read
Key Takeaway: REGENXBIO Inc. announced a conference call to be held on May 12, 2025, to discuss its financial results from Q1 2025 and recent operational highlights. The call will provide insights into the company's ongoing projects and financial performance, catering to both analysts and the public. Registration for the call and replay details are available on their investor website, emphasizing transparency and engagement with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • REGENXBIO is hosting a call to discuss positive first quarter results.
  • The company is advancing a late-stage pipeline with promising gene therapies.
  • They have collaborative partnerships enhancing their treatment capabilities.

Full Press Release Details

ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Corporate Communications
George E. MacDougall
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

When is REGENXBIO's conference call scheduled?

The conference call is on May 12, 2025, at 4:30 p.m. ET.

How can analysts participate in the Q&A session?

Analysts can join the Q&A session using a specific registration link.

Where can I find the webcast replay?

The webcast replay will be available on the company's investor website.

What is REGENXBIO's focus in biotechnology?

REGENXBIO focuses on gene therapy to improve lives, particularly rare diseases.

What diseases are targeted by REGENXBIO's therapies?

They target conditions like Duchenne, MPS II, MPS I, wet AMD, and diabetic retinopathy.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO gene therapy financial results Q1 2025
Last updated: Apr 30, 2025